Does excess visceral fat cause insulin resistance by releasing inflammatory cytokines and free fatty acids?

The hypothesis that excess visceral fat impairs insulin sensitivity by releasing inflammatory cytokines and free fatty acids is fully supported by substantial clinical and biochemical evidence. Visceral adipose tissue acts as a highly active endocrine organ that directly impairs hepatic and systemic metabolism.

Mechanistic explanations

• Cytokine-mediated signaling blocks: Visceral adipose tissue expresses and secretes high baseline levels of pro-inflammatory cytokines, specifically tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). TNF-α activates intracellular stress kinases, such as c-Jun N-terminal kinase (JNK) and inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ). These active kinases phosphorylate insulin receptor substrate-1 (IRS-1) on inhibitory serine residues (e.g., Ser307), preventing normal tyrosine phosphorylation and downstream phosphoinositide 3-kinase (PI3K)-Akt signaling.
• Lipid-induced insulin resistance: Visceral fat exhibits high rates of lipolysis, delivering a massive flux of free fatty acids (FFAs) directly into the portal vein. Within cells, these FFAs accumulate as toxic lipid intermediates, including diacylglycerols (DAG) and ceramides. DAG recruits and activates novel protein kinase C (PKC) isoforms, which phosphorylate IRS-1 on inhibitory serine residues. Concurrently, ceramides directly inhibit Akt activation, preventing the crucial translocation of glucose transporter type 4 (GLUT4) to the plasma membrane and blunting glucose uptake.

Clinical implications

• Portal vein delivery: Because visceral fat drains directly into the portal circulation, the liver is continuously exposed to elevated concentrations of FFAs and IL-6. This direct delivery impairs hepatic insulin sensitivity, stimulates hepatic triglyceride synthesis, and promotes non-alcoholic fatty liver disease (NAFLD).
• Systemic progression: The combined block of the proximal insulin signaling cascade (IRS-1-PI3K-Akt) in skeletal muscle and adipose tissue results in a failure to clear glucose from the bloodstream, driving systemic insulin resistance and escalating the risk of type 2 diabetes.

Bottom line

• Excess visceral fat acts as a primary driver of insulin resistance by releasing TNF-α, IL-6, and free fatty acids, which activate intracellular stress kinases (JNK, IKKβ, and PKC) to block downstream insulin signaling (IRS-1 serine phosphorylation and Akt inhibition), ultimately preventing GLUT4-mediated glucose uptake.